Compare Mesoblast Limited (MESO) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Taskus Inc — how do they compare? Mesoblast Limited trades at $14.32 (market cap $1.75B), while Taskus Inc trades at $8.06 (market cap $723.41M). The key difference: Mesoblast Limited is far larger — about 2.4× Taskus Inc's market cap, and Taskus Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Taskus Inc for 34 Days on average.
| MESO | TASK | |
|---|---|---|
Market Cap | $1.75B | $723.41M |
Volume | 239,027 | 201,303 |
Sector | Health | Technology |
52-Week High | $20.96 | $14.69 |
52-Week Low | $13.19 | $4.57 |
Typical Hold Time | 14 Days | 34 Days |
Enterprise Value | $1.83B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
TaskUs trades at $8.08, up 2.41% today, with a bearish technical signal but strong fundamentals including a low P/E of 6.8 and robust ROE of 25.43%. Recent Q2 2026 earnings beat estimates with $0.33 EPS versus $0.29 expected, driven by 5% revenue growth to $308.9 million. The company shows consistent cash flow generation with $137 million from operations in 2025.
The stock appears undervalued with analyst consensus target of $9.33 offering 15% upside potential. Key risks include margin compression from higher labor costs and dependence on AI segment growth. Institutional ownership increased with Dimensional Fund Advisors raising its stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
